Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 3/20 | 0.34 |
| ▸ | BCHE | P06276 | 2/20 | 0.34 |
| ▸ | CTSK | P43235 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21070332 | 0.95 | ALDH1A1 (0.38) | KDM4EALDH1A1HPGDHDAC6HDAC1 | |
| SCHEMBL31152818 | 0.93 | ALDH1A1 (0.41) | KDM4EALDH1A1HPGDHDAC6HDAC1 | |
| SCHEMBL22777483 | 0.93 | ALDH1A1 (0.41) | KDM4EALDH1A1HPGDHDAC6HDAC1 | |
| SCHEMBL21069307 | 0.93 | ALDH1A1 (0.41) | KDM4EALDH1A1HPGDHDAC6HDAC1 | |
| SCHEMBL21069899 | 0.89 | HDAC6 (0.33) | KDM4EALDH1A1HPGDHDAC6HDAC1 | |
| SCHEMBL21106335 | 0.86 | L3MBTL1 (0.34) | HDAC6HDAC1HDAC2CA14ACHE | |
| SCHEMBL21069868 | 0.85 | L3MBTL1 (0.38) | HDAC6HDAC1HDAC2CA14ACHE | |
| SCHEMBL7072100 | 0.84 | CPB2 (0.36) | KDM4EALDH1A1HPGDHDAC6HDAC1 | |
| SCHEMBL18546681 | 0.83 | CHRNB2 (0.36) | HDAC6HDAC1HDAC2ALOX5PTGS1 | |
| SCHEMBL21069506 | 0.81 | TSHR (0.44) | HDAC6HDAC1HDAC2CA14CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12528785-B2 | MDM2 degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20240424110-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-12-26 | — | — | US | disclosed |
| WO-2024129763-A1 | MODULATORS OF TNF-α ACTIVITY | FORWARD THERAPEUTICS, INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| US-11932624-B2 | MDM2 degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-03-19 | — | — | US | disclosed |
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20230295197-A1 | STAT5 and STAT6 Degraders and Uses Thereof | REGENTS OF THE UNIV OF MICHICAN (US) | 2023-09-21 | — | — | US | disclosed |
| WO-2023059792-A1 | CORONAVIRUS NON-STRUCTURAL PROTEIN 3 DEGRADING COMPOUNDS | C4 THRAPEUTICS, INC. (US) | 2023-04-13 | — | — | WO | disclosed |
| EP-4121043-A1 | MDM2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| US-20210363146-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2021-11-25 | — | — | US | disclosed |
| WO-2021188948-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| WO-2021188948-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| EP-2513054-B1 | BICYCLIC DERIVATIVES USEFUL AS INHIBITORS OF DPP-1 | JANSSEN PHARMACEUTICA NV (BE) | 2016-03-09 | — | — | EP | disclosed |
| US-8552032-B2 | Bicyclic derivatives useful as inhibitors of DPP-1 | JANSSEN PHARMACEUTICA NV (BE) | 2013-10-08 | — | — | US | disclosed |
| EP-2513054-A1 | BICYCLIC DERIVATIVES USEFUL AS INHIBITORS OF DPP-1 | Janssen Pharmaceutica, N.V. (BE) | 2012-10-24 | — | — | EP | disclosed |
| US-20110152321-A1 | BICYCLIC DERIVATIVES USEFUL AS INHIBITORS OF DPP-1 | JANSSEN PHARMACEUTICA (BE) | 2011-06-23 | — | — | US | disclosed |
| WO-2011075634-A1 | BICYCLIC DERIVATIVES USEFUL AS INHIBITORS OF DPP-1 | JANSSEN PHARMACEUTICA NV (BE) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | MDM2, TP53, MDM4 | KDM4E 1073/4885ALDH1A1 1804/4885HPGD 1968/4885 |
| US-20110152321-A1 | BICYCLIC DERIVATIVES USEFUL AS INHIBITORS OF DPP-1 | DPP4, DPP7, DPP3 | KDM4E 3534/4885ALDH1A1 194/4885HPGD 1422/4885 |
| US-20240424110-A1 | MDM2 DEGRADERS AND USES THEREOF | MDM2, USP2, MYCBP2 | KDM4E 323/4885ALDH1A1 2946/4885HPGD 3207/4885 |
| US-12528785-B2 | MDM2 degraders and uses thereof | MDM2, ADRM1, RBX1 | KDM4E 650/4885ALDH1A1 2101/4885HPGD 4011/4885 |
| US-20230295197-A1 | STAT5 and STAT6 Degraders and Uses Thereof | STAT6, STAT5B, STAT5A | KDM4E 849/4885ALDH1A1 2337/4885HPGD 3234/4885 |
| US-11932624-B2 | MDM2 degraders and uses thereof | MDM2, TP53, MDM4 | KDM4E 1073/4885ALDH1A1 1804/4885HPGD 1968/4885 |
| US-20210363146-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | MUSK, NTRK1, ERBB2 | KDM4E 3368/4885ALDH1A1 3928/4885HPGD 3152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.